Skip Navigation

David J. Kwiatkowski, MD, PhD


Medical Oncology

Make an Appointment

Physician

  • Senior Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Cancer genetics
  • Lung cancer
  • Mesothelioma
  • Personalized and targeted therapies for lung cancer and mesothelioma

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-632-6190 (established)
  • Office Phone Number857-307-0781
  • Fax617-394-2769

Bio

David Kwiatkowski is a Professor of Medicine at Harvard Medical School, and Senior Physician at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. He earned a BSc from Caltech and a PhD from MIT, both in Mathematics. He received his MD degree from Columbia University, and received the Janeway Prize at graduation for the highest achievement and abilities in the graduating medical class. He pursued Internal Medicine and then Hematology-Oncology training at the Massachusetts General Hospital, and remained at MGH until 1991 when he moved to BWH/DFCI.  Dr. Kwiatkowski has specialized in thoracic oncology, and has broad interests in all types of thoracic malignancies, including lung cancer, thymic cancer, and mesothelioma.  He is a self-trained human and cancer geneticist, and has been the leader of the Dana-Farber/Harvard Cancer Center Cancer Genetics program since 2007.  He is an Associate Member of the Broad Institute, and an active participant in The Cancer Genome Atlas (TCGA), working on multiple cancer types and programs.  His current patient research interests are: personalized/targeted treatment of cancers according to their mutations, targeting the mTOR pathway in cancer, and mesothelioma therapeutic development and treatment.  He has a much deeper familiarity with mesothelioma than the average thoracic oncologist, and sees many patients on referral from around the country.

Board Certification:

  • Internal Medicine, 1982
  • Medical Oncology, 1985

Fellowship:

  • Massachusetts General Hospital, Hematology & Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Columbia University College of Physicians & Surgeons

Recent Awards:

  • Professor of Medicine, Harvard Medical School; Senior Physician, BWH, DFCI 2004
  • NIH NINDS Javits Neuroscience Investigator Award 2007
  • Program Leader, Dana Farber Harvard Cancer Center Cancer Genetics Program 2007
  • The LAM Foundation Scientific Advancement Award 2013
  • Manuel R. Gomez Award of the Tuberous Sclerosis Alliance 2000
  • Harvard Medical School Excellence in Tutoring Award, 2010, 2011 2010, 2011

Research

mTOR signaling in cancer: therapeutic target

I have broad interests in human cancer genetics, and have been Program Leader for the DFHCC Cancer Genetics program for the past 8 years.  I am an Associate Member of the Broad Institute, and have been active in multiple NCI TCGA (The Cancer Genome Atlas) projects, including adenocarcinoma and squamous cell carcinoma of the lung, bladder cancer, kidney chromophobe cancer, mesothelioma, and pathway analyses.
 
It has become apparent that a variety of cancers (partially due to our analyses) have mutations in TSC1 or TSC2 at rates of 1 – 10%. Moreover, in some cases TSC1/TSC2-mutant cancers are highly sensitive to treatment with rapalogs, with durable CRs lasting several years. We are studying these patients to elucidate the genetic and other determinants of response to rapalogs, and investigating synergistic treatment approaches. I am the PI of a Novartis-sponsored Investigator-initiated trial to treat all cancers with mutations in either TSC1 or TSC2 with everolimus. A variety of correlative genetic studies will be done as part of that trial.

We generated a mouse model of mesothelioma due to mutation and loss of Tsc1, and demonstrated that these tumors were highly sensitive to treatment with rapalogs.  We also demonstrated some degree of mTOR activation in both mesothelioma cell lines and resected patient mesotheliomas.  This has led to enhanced interest in therapeutic strategies for mesothelioma, which although a rare malignancy overall, is commonly seen at BWH/DFCI.  I am engaged in several efforts to develop novel therapeutic approaches and clinical trials for mesothelioma.

Research Departments:

Location

Brigham and Women's Hospital
75 Francis Street
One Blackfan Circle 6-216
Boston, MA 02215
Get Directions

Top